Monitor FDA resubmission in Q2 2026 and Q2 2026 revenue for execution on production normalization. The guidance suggests a strong recovery, but near-term uncertainty remains.
Price Chart
Executive Summary
Alvotech reported Q1 2026 revenue of $105.9M, down 20.3% YoY from $132.8M, due to a production slowdown. Despite the decline, management guided for FY2026 revenue of $650-700M and adjusted EBITDA of $180-220M, implying a recovery. The company also announced a strategic manufacturing agreement with FUJIFILM and expects to resubmit BLAs to the FDA in Q2 2026.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $105.9M vs $132.8M YoY (-20.3%)
- Adjusted EBITDA $24.4M; gross margin 57%
- FY2026 guidance: revenue $650-700M, adjusted EBITDA $180-220M
- Strategic manufacturing agreement with FUJIFILM Biotechnologies
- FDA resubmission of BLAs expected in Q2 2026
Financial Impact
Revenue declined 20% YoY to $105.9M; full-year guidance implies recovery with $650-700M in revenue.
Risk Factors
- FDA resubmission delays
- Continued production disruptions
- Biosimilar competition and pricing pressure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289413 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $5.12 | awaiting T+20 | — | $4.62 (−9.77%) |
Oct 14, 2026 12d ago | 6-K | $5.17 | awaiting T+20 | — | $4.62 (−10.64%) |
Oct 7, 2026 19d ago | 6-K | $5.85 | awaiting T+20 | — | $4.62 (−21.03%) |
Oct 5, 2026 21d ago | 6-K | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Oct 5, 2026 22d ago | Press Release | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Aug 31, 2026 8w ago | 6-K | $5.19 $5.92 | ▲ +14.07% | ▲ +14.44% | $4.62 (−10.98%) |
Aug 21, 2026 9w ago | 6-K | $4.43 $5.88 | ▲ +32.73% | ▲ +31.72% | $4.62 (+4.29%) |
Aug 19, 2026 9w ago | Press Release | $4.27 $5.87 | ▼ −37.47% | ▼ −37.59% | $4.62 (−8.20%) |
Jul 29, 2026 12w ago | 6-K | $3.53 $4.91 | ▲ +39.09% | ▲ +34.07% | $4.62 (+30.88%) |
Jul 3, 2026 16w ago | Press Release | $3.46 $4.12 | ▲ +19.08% | ▲ +19.64% | $4.62 (+33.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers